Companion Animals

Companion Cat Arthritis Solensia Treatment

Anti-NGF biologic treatments for feline arthritis offer a new generation of pain management that transforms quality of life for arthritic cats.

Key Facts

Solensia (frunevetmab) is a monthly injectable anti-NGF antibody for cat arthritis pain
Clinical trials show 70-80% of cats show improvement in mobility and comfort after treatment
Cats are particularly poor at metabolising NSAIDs, making Solensia important for long-term pain management
Arthritic cats often show increased grooming, jumping, and playfulness after treatment
The drug specifically blocks the nerve growth factor pathway that drives chronic pain

Welfare Considerations

Cat arthritis is severely under-diagnosed and under-treated. Cats hide pain effectively, so many arthritic cats suffer silently for years. The development of Solensia provides a safe, effective monthly treatment specifically designed for cats who cannot safely receive long-term NSAIDs. Access to this treatment represents a transformative welfare improvement for the millions of arthritic cats who were previously managed with inadequate or no pain control.

What You Can Do

Discuss Solensia with your vet if your cat shows any signs of reduced mobility or grooming
Use validated feline arthritis assessment tools to monitor your cat's response to treatment
Advocate for routine arthritis screening in senior cats as a welfare standard